Terms: = Ovarian cancer AND CACNA1D, CCHL1A2, Cav1_3, CACNL1A2, CACN4, CACH3, ENSG00000157388, 776 AND Treatment
12 results:
1. Morphological Changes of the ovarian Vein in Pelvic Venous Disorders.
Nykonenko A; Trailin A; Lazarashvili Z; Proczka RM; Havrylenko B; Nykonenko O
Eur J Vasc Endovasc Surg; 2024 Mar; 67(3):500-505. PubMed ID: 37952635
[TBL] [Abstract] [Full Text] [Related]
2. Impact of uterus-preserving surgery on Stage I primary mucinous epithelial ovarian carcinoma: A multi-institutional study with propensity score-weighted analysis.
Yoshihara M; Kajiyama H; Tamauchi S; Iyoshi S; Yokoi A; Suzuki S; Kawai M; Nagasaka T; Takahashi K; Matsui S; Kikkawa F
Int J Gynaecol Obstet; 2020 Aug; 150(2):177-183. PubMed ID: 32469080
[TBL] [Abstract] [Full Text] [Related]
3. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary ovarian cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract] [Full Text] [Related]
4. Incidental diagnosis of tumor thrombosis on FDG PET/CT imaging.
Erhamamci S; Reyhan M; Nursal GN; Torun N; Yapar AF
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):287-94. PubMed ID: 26025479
[TBL] [Abstract] [Full Text] [Related]
5. Variation in reported experience of involvement in cancer treatment decision making: evidence from the National cancer Patient Experience Survey.
El Turabi A; Abel GA; Roland M; Lyratzopoulos G
Br J Cancer; 2013 Aug; 109(3):780-7. PubMed ID: 23807170
[TBL] [Abstract] [Full Text] [Related]
6. Anti-Müllerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia.
Iwase A; Sugita A; Hirokawa W; Goto M; Yamamoto E; Takikawa S; Nakahara T; Nakamura T; Kondo M; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2013 Apr; 167(2):194-8. PubMed ID: 23274042
[TBL] [Abstract] [Full Text] [Related]
7. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
[TBL] [Abstract] [Full Text] [Related]
8. Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001.
Oksefjell H; Sandstad B; Tropé C
Eur J Gynaecol Oncol; 2007; 28(4):256-62. PubMed ID: 17713088
[TBL] [Abstract] [Full Text] [Related]
9. ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival.
Oksefjell H; Sandstad B; Trope C
Eur J Gynaecol Oncol; 2006; 27(3):209-14. PubMed ID: 16800244
[TBL] [Abstract] [Full Text] [Related]
10. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
Masters GR; Berger MA; Albone EF
Gynecol Oncol; 2006 Sep; 102(3):462-7. PubMed ID: 16434088
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.
Berger MA; Masters GR; Singleton J; Scully MS; Grimm LG; Soltis DA; Albone EF
Cancer Biother Radiopharm; 2005 Dec; 20(6):589-602. PubMed ID: 16398611
[TBL] [Abstract] [Full Text] [Related]
12. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography.
Ueland FR; DePriest PD; Pavlik EJ; Kryscio RJ; van Nagell JR
Gynecol Oncol; 2003 Oct; 91(1):46-50. PubMed ID: 14529661
[TBL] [Abstract] [Full Text] [Related]
